NCT06982105View on ClinicalTrials.gov

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Methicillin Resistant Staphylococcus AureusOsteomyelitis AcuteSeptic ArthritisOrbital CellulitisFacial CellulitisMastoiditisCervical AdenitisRetropharyngeal AbscessPeritonsillar Abscess
Interventions
DRUG

Trimethoprim Sulfamethoxazole

"* For osteoarticular infections- 4-5 mg/kg/dose (based on TMP) PO every 8 hours (max dose 320mg/dose)~* For head and neck infections- 5-6 mg/kg/dose (based on TMP PO every 12 hours (max dose 320mg/dose)~Duration will be at the discretion of the treating provider"

Trial Locations (1)

46202

RECRUITING

Riley Hospital for Children, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER